Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target

(2016) Jiancheng Zhou et al.   CANCER LETTERS

Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells

(2016) Bing Long et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

(2016) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation

(2016) Silvana Sandri et al.   PHARMACOLOGICAL RESEARCH

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

(2015) Alexander M. Menzies et al.   CANCER

Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44+/Musashi-1+ gastric cancer stem cells

(2015) Min Xu et al.   CANCER LETTERS

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

(2015) Inna V. Fedorenko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells

(2015) Y-H Fan et al.   ONCOGENE

Glycated Reconstructed Human Skin as a Platform to Study the Pathogenesis of Skin Aging

(2015) Paula Comune Pennacchi et al.   TISSUE ENGINEERING PART A

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

(2015) Matteo Dugo et al.   Oncotarget

Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened

(2015) Annelies Gonnissen et al.   Oncotarget

Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance

(2015) Komaraiah Palle et al.   Cancers

PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

(2015) Francesco Sabbatino et al.   Oncotarget

Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449)

(2014) Rowena E Meani et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Hedgehog-GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer

(2014) L. Huang et al.   CLINICAL CANCER RESEARCH

Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression

(2014) Hai-Xia Fan et al.   MEDICAL ONCOLOGY

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

(2014) Matteo S. Carlino et al.   Molecular Oncology

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors

(2013) Marilena Tauro et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner

(2013) Jianjun Lei et al.   Molecular Cancer

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Apoptosis therapy: driving cancers down the road to ruin

(2013) Douglas R. Green et al.   NATURE MEDICINE

TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma

(2013) Dinoop R. Menon et al.   Pigment Cell & Melanoma Research

Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells

(2013) Fernanda Faião-Flores et al.   TUMOR BIOLOGY

TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction

(2013) V Tirino et al.   Cell Death & Disease

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

(2013) Jessie Villanueva et al.   Cell Reports

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Crosstalk between TGF-β and hedgehog signaling in cancer

(2012) Delphine Javelaud et al.   FEBS LETTERS

Melanoma: from mutations to medicine

(2012) H. Tsao et al.   GENES & DEVELOPMENT

Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growthin vitroandin vivo

(2012) Malin Wickström et al.   INTERNATIONAL JOURNAL OF CANCER

B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line

(2012) Huimin Zhou et al.   IUBMB LIFE

Expression of Microphthalmia-associated Transcription Factor (MITF), Which Is Critical for Melanoma Progression, Is Inhibited by Both Transcription Factor GLI2 and Transforming Growth Factor-β

(2012) Marie-Jeanne Pierrat et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin

(2012) Deng Pan et al.   LEUKEMIA RESEARCH

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

(2012) A. D. Steg et al.   MOLECULAR CANCER THERAPEUTICS

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

(2012) Pieter J A Eichhorn et al.   NATURE MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death

(2012) Carla A. Brohem et al.   Pigment Cell & Melanoma Research

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

TGF- /SMAD/GLI2 Signaling Axis in Cancer Progression and Metastasis

(2011) D. Javelaud et al.   CANCER RESEARCH

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

(2011) Franziska Niehr et al.   Journal of Translational Medicine

GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells

(2011) Delphine Javelaud et al.   Pigment Cell & Melanoma Research

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Resistance to transforming growth factor  -mediated tumor suppression in melanoma: are multiple mechanisms in place?

(2010) A. Lasfar et al.   CARCINOGENESIS

GLI2-Mediated Melanoma Invasion and Metastasis

(2010) Vasileia-Ismini Alexaki et al.   JNCI-Journal of the National Cancer Institute

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells

(2010) K C S Queiroz et al.   ONCOGENE

Artificial skin in perspective: concepts and applications

(2010) Carla A. Brohem et al.   Pigment Cell & Melanoma Research

The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes

(2009) Hong Yu et al.   AMERICAN JOURNAL OF PATHOLOGY

Cloning of the HumanGLI2Promoter

(2009) Sylviane Dennler et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo

(2009) Florence Debacq-Chainiaux et al.   Nature Protocols

GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer

(2008) S. Narita et al.   CLINICAL CANCER RESEARCH

Transforming growth factor-β in cutaneous melanoma

(2008) Delphine Javelaud et al.   Pigment Cell & Melanoma Research